$AVTX Cashflow Statement | Understand Stock

$AVTX

$6.75 -$0.02 (0.3%) Close

$AVTX Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated Statements of Cash Flows

In millions of USD, except per-share amounts

	FY2025 12 months to Dec 31, 2025	FY2024 12 months to Dec 31, 2024	FY2023 12 months to Dec 31, 2023	FY2022 12 months to Dec 31, 2022	FY2021 12 months to Dec 31, 2021
Operating activities
Net loss
Adjustments to reconcile net loss used in operating activities:
Depreciation and amortization
Stock-based compensation
Accretion of available-for-sale investments, net
Change in fair value of derivative liability
Acquired in-process research and development
Excess of initial warrant fair value over private placement proceeds
Change in fair value of warrant liability
Transaction costs paid pursuant to private placement
Transaction costs paid upon exercise of warrants issued in private placement
Contingent consideration paid pursuant to AlmataBio Transaction
Lease early termination fee
Accretion of debt discount
Allowance for other long-term asset
Acquired in-process research and development, including transaction costs
Change in fair value of Investment in Aytu
Change in value of Guarantee
Change in fair value of warrant liability and unit purchase option liability
Goodwill impairment
Deferred taxes
Changes in assets and liabilities:
Accounts receivable, net
Other receivables
Other long-term asset
Inventory, net
Prepaid expenses and other assets
Lease incentive
Accounts payable
Income taxes payable
Deferred revenue
Accrued expenses and other liabilities, excluding lease liability
Lease liability, net
Derivative liability

Net cash used in operating activities
Investing activities
Proceeds from sale of Investment in Aytu, net
Net cash paid in merger with Aevi
Purchase of investments
Maturities of investments
Cash assumed from AlmataBio Transaction
Leasehold improvements
Disposal of property and equipment
Purchase of property and equipment
Net cash (used in) provided by investing activities

Financing activities
Proceeds from sale of common stock pursuant to ATM Program, net
Proceeds from registered direct offering, net
Proceeds from sale of common stock pursuant to ATM Program
Proceeds from issuance of common stock in underwritten public offering, net
Proceeds from Notes and warrants, net of debt issuance costs paid
Principal payments on Notes
Transaction costs paid pursuant to ATM Program
Proceeds from exercise of stock options
Proceeds from issuance of common stock under employee stock purchase plan, net of cash paid related to withholding shares to satisfy tax withholding obligations
Cash paid related to withholding shares to satisfy RSU tax withholding obligations
Proceeds from private placement investment, gross
Transaction costs paid pursuant to private placement
Proceeds from exercise of warrants issued in private placement, gross
Transaction costs paid upon exercise of warrants issued in private placement
Net cash provided by financing activities

(Decrease) increase in cash, cash equivalents, and restricted cash
Cash, cash equivalents, and restricted cash at beginning of period
Cash, cash equivalents, and restricted cash at end of period
Cash paid for interest
Cash paid for taxes
Supplemental disclosures of non-cash activities
Leased asset obtained in exchange for new operating lease liability
Issuance of common stock in Aevi Merger
Issuance of common stock and Series C Preferred Stock pursuant to AlmataBio Transaction
Remeasurement of lease
Fair value of common stock retired in exchange for issuance of pre-funded warrants

Cash and cash equivalents
Restricted cash, current
Restricted cash, non-current

Comments